Here's Why Axsome Therapeutics Fell 10.2% in February
Shares of Axsome Therapeutics (NASDAQ: AXSM) fell over 10% last month, according to data provided by S&P Global Market Intelligence. The broader markets were down as investors considered the economic impacts of steps taken to contain regional coronavirus outbreaks. Those fears have only deepened in March.
There wasn't any negative news specific to the company in February. Of course, Axsome Therapeutics was one of the best stocks on the market in 2019, which positions the pharma stock as a prime target for a tumble during corrections. Investors with a long-term mindset shouldn't see any new reasons for concern. All eyes should remain on the important updates expected in March.
Image source: Getty Images.
Source Fool.com
